Comment: Niraparib for ovarian cancer

Bookmark and Share
Published: 10 Oct 2016
Views: 1404
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Dr De Azambuja reviews data released at ESMO 2016 relating to the use of PARP inhibitor niraparib in platinum-sensitive recurrent ovarian cancer.

Read the news story or watch the interview or press conference with the investigator himself, Dr Mansoor Raza Mirza, for more.